US20020064858A1 - Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria - Google Patents
Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria Download PDFInfo
- Publication number
- US20020064858A1 US20020064858A1 US09/140,888 US14088898A US2002064858A1 US 20020064858 A1 US20020064858 A1 US 20020064858A1 US 14088898 A US14088898 A US 14088898A US 2002064858 A1 US2002064858 A1 US 2002064858A1
- Authority
- US
- United States
- Prior art keywords
- bacteria
- chondroitinase
- alginate
- degrading enzyme
- heparinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 114
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 58
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 58
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims abstract description 55
- 230000000593 degrading effect Effects 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims description 28
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 36
- 238000009877 rendering Methods 0.000 claims abstract description 9
- 229920000615 alginic acid Polymers 0.000 claims description 105
- 235000010443 alginic acid Nutrition 0.000 claims description 105
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 100
- 229940072056 alginate Drugs 0.000 claims description 100
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 68
- 229940088598 enzyme Drugs 0.000 claims description 56
- 208000015181 infectious disease Diseases 0.000 claims description 45
- 210000004072 lung Anatomy 0.000 claims description 38
- 230000001580 bacterial effect Effects 0.000 claims description 29
- 230000002685 pulmonary effect Effects 0.000 claims description 23
- 241000589516 Pseudomonas Species 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 230000003115 biocidal effect Effects 0.000 claims description 18
- 230000001684 chronic effect Effects 0.000 claims description 18
- 108010006406 heparinase II Proteins 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 18
- 230000000844 anti-bacterial effect Effects 0.000 claims description 17
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 16
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 claims description 16
- 229960002773 hyaluronidase Drugs 0.000 claims description 16
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 claims description 13
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 claims description 13
- 239000003899 bactericide agent Substances 0.000 claims description 13
- 108010035886 connective tissue-activating peptide Proteins 0.000 claims description 12
- -1 glucoronidase Proteins 0.000 claims description 12
- 102100036154 Platelet basic protein Human genes 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 10
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 10
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 claims description 9
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 claims description 9
- 108010022901 Heparin Lyase Proteins 0.000 claims description 9
- 102000004317 Lyases Human genes 0.000 claims description 8
- 108090000856 Lyases Proteins 0.000 claims description 8
- 108010083213 heparitinsulfate lyase Proteins 0.000 claims description 8
- 108010053927 Iduronate Sulfatase Proteins 0.000 claims description 7
- 101710106625 Chondroitinase-AC Proteins 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 102000005262 Sulfatase Human genes 0.000 claims description 6
- 108010048429 chondroitinase B Proteins 0.000 claims description 6
- 108060007951 sulfatase Proteins 0.000 claims description 6
- 241000973034 Azomonas Species 0.000 claims description 5
- 241000589151 Azotobacter Species 0.000 claims description 5
- 102000004157 Hydrolases Human genes 0.000 claims description 5
- 108090000604 Hydrolases Proteins 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 230000002132 lysosomal effect Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 241000605909 Fusobacterium Species 0.000 claims description 4
- 241000588748 Klebsiella Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 241000589886 Treponema Species 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 108010037536 heparanase Proteins 0.000 description 38
- 102100024025 Heparanase Human genes 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 229940088710 antibiotic agent Drugs 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 210000003097 mucus Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 8
- 229930182566 Gentamicin Natural products 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 229920002444 Exopolysaccharide Polymers 0.000 description 6
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 6
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 239000001974 tryptic soy broth Substances 0.000 description 6
- 108010050327 trypticase-soy broth Proteins 0.000 description 6
- 230000001018 virulence Effects 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 229960004821 amikacin Drugs 0.000 description 5
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 description 4
- 229920002971 Heparan sulfate Polymers 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000003139 biocide Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940059329 chondroitin sulfate Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 244000039328 opportunistic pathogen Species 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000007201 ts agar Substances 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 241000605114 Pedobacter heparinus Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 3
- 210000001552 airway epithelial cell Anatomy 0.000 description 3
- 101150113943 algD gene Proteins 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- KDHHWXGBNUCREU-HOTGVXAUSA-N Ferric-aerobactin Chemical compound CC(=O)N(O)CCCC[C@@H](C(O)=O)NC(=O)CC(O)(C(O)=O)CC(=O)N[C@H](C(O)=O)CCCCN(O)C(C)=O KDHHWXGBNUCREU-HOTGVXAUSA-N 0.000 description 2
- 108010034448 GDPmannose dehydrogenase Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 108050009363 Hyaluronidases Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 108010038016 Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 2
- 108091022912 Mannose-6-Phosphate Isomerase Proteins 0.000 description 2
- 102000048193 Mannose-6-phosphate isomerases Human genes 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000010062 adhesion mechanism Effects 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003095 anti-phagocytic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229960000740 enrofloxacin Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 101150005437 mucA gene Proteins 0.000 description 2
- 230000003843 mucus production Effects 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000018612 quorum sensing Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- WOIAAVJAGKBTTQ-AWEZNQCLSA-N (2s)-4-hydroxy-2-(3-oxododecanoylamino)butanoic acid Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H](C(O)=O)CCO WOIAAVJAGKBTTQ-AWEZNQCLSA-N 0.000 description 1
- CJAOGUFAAWZWNI-UHFFFAOYSA-N 1-n,1-n,4-n,4-n-tetramethylbenzene-1,4-diamine Chemical compound CN(C)C1=CC=C(N(C)C)C=C1 CJAOGUFAAWZWNI-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- PDMUULPVBYQBBK-UHFFFAOYSA-N 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone Chemical compound C1=C(OC)C(OCCCC)=CC(CC2NC(=O)NC2)=C1 PDMUULPVBYQBBK-UHFFFAOYSA-N 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000032840 Catheter-Related Infections Diseases 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 1
- 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 1
- 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 1
- 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 1
- 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 1
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- QJPWUUJVYOJNMH-VKHMYHEASA-N L-homoserine lactone Chemical compound N[C@H]1CCOC1=O QJPWUUJVYOJNMH-VKHMYHEASA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 1
- 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 1
- 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000157908 Paenarthrobacter aurescens Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 101100162454 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) algR gene Proteins 0.000 description 1
- 101100361766 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) algU gene Proteins 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589755 Pseudomonas mendocina Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 1
- 102000004002 Secretory Leukocyte Peptidase Inhibitor Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 1
- 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 1
- 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 1
- 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 1
- 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 1
- 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 1
- 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 1
- 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000009327 acute endophthalmitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000025845 adhesion to host Effects 0.000 description 1
- 101150115466 algB gene Proteins 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000007924 bacterial virulence factor Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- KFEUJDWYNGMDBV-RPHKZZMBSA-N beta-D-Galp-(1->4)-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-RPHKZZMBSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 229940091926 enroflox Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 102000046975 human DEFB1 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000382 optic material Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01166—Heparanase (3.2.1.166)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02008—Heparin-sulfate lyase (4.2.2.8)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Definitions
- the present invention relates to the use of glycosaminoglycans degrading enzymes, such as, but not limited to, heparanases, connective tissue activating peptide III (CTAP), heparinases, hyaluronidases and chondroitinases, against surface protected bacteria, for reduction of bacterial alginate and for the disruption of bacterial biofilms. More particularly, the present invention relates to the use of glycosaminoglycans degrading enzymes for treating conditions resulting from infection by mucoid, alginate-producing and/or biofilm-producing bacteria.
- CTP connective tissue activating peptide III
- Glycosaminoglycans degrading enzymes Glycosaminoglycans (GAG) are unbranched polyanionic polysaccharides made up of repeating disaccharides. One component of which is always an amino sugar. Degradation of GAG is carried out by a battery of lysosomal hydrolases.
- endoglycosidases heparanse and CTAP degrade heparan sulfate and to a lesser extent heparin, and hyaluronidase from sheep or bovine testes degrade hyaluronic acid and chondroitin sulfate
- various exoglycosidases ⁇ -glucoronidase
- sulfatases iduronate sulfatase
- Bacterial lyases such as heparinase I, II and III from Flavobacterium heparinum cleave heparin-like molecules, chondroitinase ABC from Proteus vulgaris, AC from Arthrobacter aurescens or Flavobacterium heparinum, B and C from Flavobacterium heparinum degrade chondroitin-sulfate.
- Pseudomonas aeruginosa is an opportunistic pathogen responsible for a wide range of infections, one of the most debilitating being chronic pulmonary infection in cystic fibrosis (CF) patients.
- CF cystic fibrosis
- the basic alteration in the bronchial/pulmonary environment of the CF lung causing increased secretion of hyperviscous mucus favors bacterial colonization by Staphylococcus aureus, Haemophilus influenzae and P. aeruginosa. Prolonged antibiotic therapy and the increasing life expectancy of CF patients may influence the prevalence of all of these organisms in the lung flora. P.
- aeruginosa is found in patients with moderate and severe pulmonary disease, being the sole pathogen found in sputum in the most advanced stages of the disease. P. aeruginosa is particularly resistant to even the most aggressive chemotherapy and has been found to colonize the lungs of 50-90% of all CF patients. It has been shown that the severity of lung infection in CF patients is directly correlated to the presence of mucoid strains. The mucoid P. aeruginosa isolates revert at a high frequency to a nonmucoid form upon serial transfers in the laboratory.
- Alginate appears to protect P. aeruginasa by shielding it from host immune defense and antibiotic therapy, and possibly enables it to adhere more effectively to respiratory tract tissues. Once established in the CF lung, these mucoid strains tend to persist and parallel the progressive clinical deterioration of the patient.
- Alginate is a linear acetylated copolymer consisting of ⁇ -1,4-linked D-mannuronic acid and variable amounts of its C-5 epimer L-guluronic acid.
- Alginate is produced by several bacterial species, the most widely known being Azotobacter vinelandii and P. aeruginosa. Bacterial alginates differ from algal alginate in that the former contain O-acetyl groups. The viscosity level of alginate may play a role in the pathogenesis of mucoid P. aeruginosa in the CF respiratory tract.
- Several enzymes are involved in the alginate biosynthetic pathway: Phosphomannose isomerase (PMI), GDP-mannose dehydrogenase (GMD), and GDP-mannose pyrophosphorylase (GMP) in mucoid, alginate-producing P. aeruginose. Activities of the enzymes are either absent or greatly reduced in nonmucoid strains.
- Alginate synthesis by the highly mucoid P. aeruginosa 8821 M is growth-phase-dependent and the alginate produced per unit of biomass reaches maximum values in the deceleration phase of growth.
- the degree of polymerization increases as batch growth proceeds, reaching maximum values at the stationary phase of growth (Leitao J H, Sa-Correia I; Arch Microbiol March 1995; 163(3): 217-222).
- aeruginosa alg genes Southern hybridization studies using algA, pmm, algD, and algR1 as probes showed some degree of homology with several Pseudomonas species belonging to Pseudomonas RNA homology group 1. Some probes also hybridized with Azotobacter, Azomonas, and Serpens species. In the laboratory, the alginate-producing (alg+) phenotype is somewhat unstable, and nonmucoid (alg ⁇ ) revertants are commonly seen.
- aeruginosa may lead to treatments that could turn off alginate production by the organisms resident in the CF lung, thus improving the longevity and quality of life for these patients (Pseudomonas: biotransformations, pathogenesis, and evolving biotechnology. Edited by Simon Silver et al., 1990 Am. Soc. For Microbiol. Ch. 2 and 3, pp. 15-36)
- Adhesion mechanisms of P. aeruginosa Adherence through carbohydrate-binding adhesins is an early step in colonization of the lung by gram-negative organisms (Azghani AO et al.; Glycobiology February 1995; 5(1): 39-44).
- Pseusomonas aeruginosa is an opportunistic pathogen capable of causing serious localized infections of the cerebrospinal fluid (CSF), urinary tract, eye, ear, lung, skin, and other parts of the body.
- CSF cerebrospinal fluid
- the organism is often isolated from peritoneal dialysis membranes. Generalized systemic infections tend to occur only in injured, immunodeficient, or otherwise compromised patients.
- mucoid strains of Pseudomonas adhere much better to tracheal cells compared to nonmucoid strains or compared to alginate-producing bacteria grown in an antibiotic medium to reduce alginate production.
- Alginate appears to play a role in the adhesion of Pseudomonas to contact lenses. Microscopic evidence suggests that mucoid strains may adhere to ciliated tracheal cells and to inert surfaces, including contact lenses, by polysaccharide-like materials. The presence of alginate in the reaction mixture causes an increase in the number of bacteria adherent to tracheal cells or immobilized mucin.
- the alginate may act to trap and tether the organisms to the substrata, thereby allowing other adhesins, such as the fimbrial adhesin complex, to bind the specific receptors. If the target animal cell or substrata lacks the ability to bind alginate, then the presence of an exopolysaccharide coat on the bacterial surface may actually impede the ability of the organisms to attach to such animal cells. This may explain the rescued ability of the mucoid strains to bind to phagocytic cells or to primary cultures of cilliated epithelial cells. The phagocytic cells lack the ability to bind alginate.
- adhesion of P. aeruginosa to various substrata may involve lectins specific for carbohydrates other than sialic acid.
- adhesion of the bacteria to the tracheal epithelium is inhibited by D-galactose and N-acetyl-D-glucosamine.
- putative nonfimbrial adhesins produced by both mucoid and nonmucoid strains of Pseudomonas, specific for Gal ⁇ 1, 4GlcNAc or Gal ⁇ 1, 3GlcNAc sequences, may be involved in mediating binding of the organisms to human bronchial mucins (Bacterial Adhesion to Cells and Tissues/Ofek I and Doyle R J, 1994 Chapman & Hall, Inc. pp. 114-116, 418-421).
- P. aeruginosa biofilms Bacteria in nature often exist as sessile communities called biofilms. These communities develop structures that are morphologically and physiologically differentiated from free living bacteria. A cell-to-cell signal is involved in the development of P. aeruginosa biofilms. The involvement of an intercellular signal molecule in the development of P. aeruginosa biofilms suggests possible targets to control biofilm growth on catheters, in CF and in other environments where P. aerugiosa biofilms are a persistent problem. Biofilms of P. aeruginosa develop on solid surfaces exposed to a continuous flow of nutrients.
- the biofilm structures consist primarily of an exopolysaccharide matrix or glycocalyx in which the bacteria are embedded.
- Cell to cell signal is required for the differentiation of individual cells of the common bacterium P. aeruginosa into complex multicellular structures.
- P. aeruginosa cells in biofilms secrete a particular homoserine lactone, 3-oxododecanoylhomoserine (OdDHL), that helps to control biofilm differentiation.
- OdDHL binds an R-protein inside the target cell, activating RNA polymerases that are involved in forming the biofilm.
- a mutation that blocks generation of the signal molecule hinders differentiation, and the resulting abnormal biofilm appears to be sensitive to the detergent biocide SDS.
- biofilm differentiation and integrity by quorum sensing has important implications in medicine. Because of their innate resistance to antibiotics and other biocides, biofilms in these environments are difficult, if not impossible, to eradicate. Bacterial biofilms also present other problems of significant economic importance in both industry and medicine. The finding of a connection between biofilm differentiation into clusters of bacteria resistant to the detergent biocide SDS and a quorum-sensing signal suggests that inhibition of these cell-to-cell signals could aid in the treatment of biofilms (Davies D G et al.; Science vol 280 Apr. 10, 1998).
- Biofilms are also an integral part of dental plaque, thereby contributing to tooth decay and periodontal disease.
- One target is Fusobacterium nucleatum, an oral bacteria found in biofilms coating the area between teeth and gums (Potera C; ASM News, 64(6), 1998).
- aeruginosa adheres to the optic material of intraoccular lenses: AcrySof-acrylic ⁇ PMMA ⁇ silicone 1 ⁇ silicon 2, and form biofilms (Manal M et al.; J Cataract Refract Surg vol. 24, January 1998).
- CF lung predilection for excessive inflammation and infection with P. aeruginosa In CF, defective function of the CFTR in airway epithelial cells and submucosal glands, results in chronic pulmonary infection with P. aeruginosa. The pulmonary infection incites an intense host inflammatory response, causing progressive suppurative pulmonary disease. Several hypotheses have been proposed to explain CF lung predilection for excessive inflammation and infection with P. aeruginosa.
- alginate The role of alginate in pathogenesis is complex and appears to confer antiphagocytic properties and an adherence mechanism upon the organism. Autopsies show that mucoid P. aeruginosa forms adherent microcolonies in the lung. Alginate does not firmly adhere to the organisms but is released in large quantities into the respiratory environment. Because alginate is very viscous in aqueous solution, it probably contributes to the high viscosity of the bronchial secretions in the CF lung, resulting in obstruction of small airways, interference with mucociliary airway clearance, and impaired movement to phagocytes.
- the mucoid organisms may be more adapted to a chronic infection because they secrete lower levels of proteases, which would otherwise cause extensive lung damage and acute infection.
- P. aeuruginosa can utilize the respiratory secretions of the CF lung to support rapid growth and alginate biosynthesis; thus, the mucus-congested CF respiratory tract provides P. aeruginosa with a nutritionally rich environment favorable to clonization.
- the initial colonization of the CF upper respiratory tract appears to be with a nonmucoid strain and is often asympomatic. This usually precedes the emergence of mucoid variants of the original strain and is followed by chronic infection and a poor prognosis for the patient.
- CF patients do produce opsonic antibodies to mucoid P. aeruginosa that are in a planktonic or suspended state, but these antibodies fail to kill P. aeruginosa growing in a biofilm (Pier G B; Behring Inst Mitt February 1997; 98: 350-60). Results showed that alginate and neutral polysaccharides are involved in phagocytic impairment of P. aeruginosa (Pasquier C et al.; FEMS Microbiol Lett Feb. 15, 1997; 147(2): 195-202).
- aeruginosa may be a critical factor in hyper susceptibility of CF patients to chronic lung infections (Pier G B et al.; Am J Respir Crit Care Med October 1996; 154(4 Pt 2): S175-82; Proc Natl Acad Sci U S A Oct. 28, 1997; 94(22): 12088-93).
- the majority of CF mucoid isolates carry mucA mutations which allow transcription of alginate biosynthetic genes, resulting in a mucoid phenotype.
- Mucoidy is caused by muc mutations that depress the alternative sigma factor encoded by algU, which in turn activates alginate biosynthetic and ancillary regulatory genes (Boucher J C et al.; Infec Immun September 1997; 65: 3838-46; Boucher J C et al.; J Bacteriol January 1996; 178(2): 511-23). Mucoid cells are cleared less efficiently and appears to linger in the lung longer that nonmucoid organisms. This finding suggests that mucoidy may confer an ability to resist innate clearance mechanisms in the lung and, along with other potentially contributing factors, could be the basis for selection of mucA mutants in CF (Yu H et al.; Infec and Immun. 1998, 66(1): 280-88). Another possibility is that Pseudomonas adheres to epithelial cells in the CF airway in greater numbers because of the abnormal surface properties of the cells, thus leading to infection.
- P. aeruginosa is a remarkable opportunistic pathogen and has adapted the alginate conversion system to promote debilitating and life threatening pulmonary infections of CF patients.
- the environment of the CF lung is unique in its capacity to induce alginate production by P. aeruginosa.
- the factors which contribute to this unusual host-pathogen interaction have not yet been determined.
- CF is the most common fatal genetic disease among the Caucasian population, affecting approximately 1:2500 newborns.
- the median age of survival of patients with CF has dramatically increased over the past 2 decades from less than 10 to more than 30 years. This progress has occurred primarily through improved nutritional support and aggressive management with antibiotic therapy of acute pulmonary infections.
- therapies which completely eradicates alginate-producing P. aeruginosa from the CF lung environment.
- the development of new compounds effective in preventing alginate synthesis represents a major step towards reaching this goal.
- Such inhibitors of alginate synthesis have potential clinical applications in that elimination of the alginate capsule might render P. aeruginosa more susceptible to both antibiotic therapy and the host's immune system.
- Mrnsy R J et al. have investigated the use of an alginate lyase obtained from a bacterial source to disrupt P. aeruginosa alginate's polymeric nature and effect a change in the Theological properties of CF sputum in vitro.
- a 41 kDa alginate lyase capable of degrading alginic acid of P. aeruginosa was prepared from the culture of Bacillus strain ATB-1015. The enzyme was found useful for the treatment of respiratory diseases caused by infection by P. aeruginosa (JP 95-181047, JP 09009962 A2 to Akira Nakagawa). Alginic acid lyase(s) which decompose alginic acid into sugar and the 4-deoxy-5-keto uronic acid is used for treatment of pulmonary cystic fibrosis (JP 06197760 A to Yakuhin Otsuka). However, these lyases fail to degrade glycosaminoglycans.
- Phagocytosis of P. aeruginosa by macrophages is a unique two-step process; binding is glucose-independent but ingestion occurs only in the presence of D-glucose or D-mannose. Since glucose is present in only negligible quantities in the endobroncheal space, P. aeruginosa may be pathogenic by virtue of its capacity to exploit the opportunity presented in the lower airway to resist normal nonspecific phagocytic defenses.
- alginate may be an important factor in determining the local distribution of leukocyte elastase and perturbing the overall protease-antiprotease balance in the infected lungs of CF patients (Ying Q L et al.; Am j Respir Cell Mol Biol. August 1996; 15(2): 283-91).
- K. pneumoniae K1 synthesizes capsular polysaccharide.
- Non mucoid variants thereof are more susceptible to some bacteriophages, possibly due to the reduction or absence of capsular polysaccharide (Mengistu Y et al.; J Appl Bacteriol May 1994, 76(5): 424-30).
- Mucoid or highly encapsulated strains of group A Streptococci have been associated both with unusually sever infections and with acute rheumatic fever.
- the mucoid M-type 18 strain of a group A Streptococcus has a hyaluronic acid capsule which plays an important role in virulence.
- the region of the chromosome essential for capsular polysaccharide expression is conserved among diverse group A streptococcal strains. Wessels M R et al.; Infec Immun February 1994; 62(2): 433-41.
- the antiphagocytic effect of M protein has been considered a critical element in virulence of the group A Streptococcus.
- the hyaluronic acid capsule also appeared to play an important role: studies of an acapsular mutant derived form the mucoid or highly encapsulated M protein type 18 group A strepococcal strain 282 indicated that loss of capsule expression was associated with decreased resistance to phagocytic killing and with reduced virulence in mice. The results provide further evidence that the hyaluronic acid capsule confers resistance to phagocytosis and enhances group A streptococcal virulence. Moses A E et al.; Infect Immun. January 1997; 65(1): 64-71.
- Staphylococcus aureus arthritis is a rapidly progressive and highly erosive disease of the joints in which both host and bacterial factors are of pathogenic importance.
- One potential bacterial virulence factor is the ability to express a polysaccharide capsule (CP).
- CP type 5 CP5
- CP8 comprise 80-85% of all clinical blood isolates. The results clearly indicated that the expression of CP5 is a determinant of the virulence of S. aureus in arthritis and septicemia (Nilsson I M et al.; Infec Immun 1 October; 65(10): 4216-21).
- Treponema denticola which has been associated with periodontitis, synthesizes or acquires and extracellular polysaccharide layer (Scott D et al; Oral Microbiol Immunol April 1997, 12(2): 121-5).
- the above described data implies that there is a widely recognized need for, and it would be highly advantageous to have agents effective in reducing mucus production by bacteria, by, for example, degradation or prevention of synthesis of the bacterial exopolysaccharide alginate.
- the benefits from employing such agents for the degradation of bacterial exopolysaccharide alginate include (i) viscosity reduction of alginate related hyperviscous bronchial secretions; (ii) disruption of bacterial biofilms which may render the bacteria more susceptible to host immune defense systems and antibiotic therapy; (iii) inhibition of alginate associated adhesion to host cells and enhancement of bacterial clearance, resulting in reduction of infection rate; (vi) reduction of host's inflammatory response to infection.
- a method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent comprising the step of subjecting the bacteria to a glycosaminoglycans degrading enzyme.
- a method of rendering a surface protected bacteria less capable of adhering to a substratum comprising the step of subjecting the bacteria to a glycosaminoglycans degrading enzyme.
- a method of treating a disease for relieving disease associated symptoms comprising the step of administering a therapeutical composition including a glycosaminoglycans degrading enzyme.
- a therapeutic composition for treating a surface protected bacteria associated disease or symptoms comprising a glycosaminoglycans degrading enzyme and an antibiotic.
- a bactericide composition effective in eliminating a surface protected bacteria comprising a glycosaminoglycans degrading enzyme and a bactericide.
- the surface protected bacteria is a mucoid bacteria.
- the surface protected bacteria is an alginate-producing bacteria.
- the surface protected bacteria is a biofilm-producing bacteria.
- the anti-bacterial agent is a bactericide.
- the anti-bacterial agent is an antibiotic.
- the anti-bacterial agent is an immune moiety.
- glycosaminoglycans degrading enzyme is selected from the group consisting of a lysosomal hydrolase and a bacterial lyase.
- glycosaminoglycans degrading enzyme is selected from the group consisting of an endoglycosidase, an exoglycosidase and a sulfatase.
- the glycosaminoglycans degrading enzyme is selected from the group consisting of heparanse, connective tissue activating peptide III (CTAP), hyaluronidase, glucoronidase, iduronate sulfatase, heparinase I, heparinase II heparinase III, chondroitinase ABC, chondroitinase AC, chondroitinase B and chondroitinase C.
- CTAP connective tissue activating peptide III
- hyaluronidase hyaluronidase
- glucoronidase glucoronidase
- iduronate sulfatase heparinase I, heparinase II heparinase III
- chondroitinase ABC chondroitinase AC
- chondroitinase B chondroitinase C.
- the bacteria is of a genus selected from the group consisting of Pseudomonas, Azotobacter, Azomonas, Serpens, Fusobacterium, Klebsiella, Streptococcus, Staphylococcus and Treponema
- the bacteria is of a genus Pseudomonas
- the bacteria is Pseudomonas aeruginosa
- the bacteria is in a lung of a patient suffering chronic pulmonary infection, the method being for relieving symptoms associated with the chronic pulmonary infection.
- the bacteria is in a lung of a cystic fibrosis patient suffering chronic pulmonary infection, the method being for relieving symptoms associated with the chronic pulmonary infection.
- the bacteria is growing on a non-living substratum.
- the non-living substratum forms a part of a medical device.
- the medical device is selected from the group consisting of an infusion device, a catheter device, a contact lens device, a dialysis device and a draining device.
- the present invention successfully addresses the shortcomings of the presently known configurations by providing methods and compositions effective in combating surface protected bacteria (e.g., mucoid-, alginate-, biofilm-producing bacteria), by subjecting such bacteria to glycosaminoglycans degrading enzyme, rendering such bacteria surface non-protected and therefore more susceptible to anti-bacterial agents and less capable of adhering to various living and non-living substrata.
- surface protected bacteria e.g., mucoid-, alginate-, biofilm-producing bacteria
- FIG. 1 demonstrates the monosaccharide composition of mucoid P. aeruginosa isolate No. 1 (samples 11, 12) and of three sputum samples from CF patients (samples 1, 6, 24), as well as of heparan sulphate standard (HS1), chondroitin sulfate A (G9), and of monosaccharide standard ladder (G8).
- HS1 heparan sulphate standard
- G9 chondroitin sulfate A
- G8 monosaccharide standard ladder
- FIGS. 2 a - e demonstrate the effect of heparanase on the amount of mucus produced by mucoid P. aeruginosa isolate No. 1.
- Bacteria were plated on tryptic soy agar ( 2 a - d ) or McConkey agar ( 2 e ). Discs soaked with the examined compound were placed on top.
- FIGS. 3 a - b demonstrate the effect of heparanase on sensitivity to antibiotics.
- 2 a Bacteria were plated on tryptic soy agar following treatment with (from left to right, top to bottom) heparanase buffer, heparanase, boiled heparanase, chondroitinase ABC, hyaluronidase or heparinase II.
- Antibiotic discs were placed according to the scheme in FIG. 3 b.
- FIGS. 4 a - e demonstrate the effect of heparanase on mucoid P. aeruginosa isolate No. 40 proliferation rate and sensitivity to antibiotics.
- 4 b - e The proliferation rate as in FIG.
- the present invention is of methods and compositions effective in combating mucoid, alginate-producing and/or biofilm-producing bacteria, by subjecting such bacteria to glycosaminoglycans degrading enzymes, which can be used, for example, to treat infections caused by such virulent bacteria.
- the present invention can be used for the reduction of mucus production by mucoid P.
- aeruginosa and other mucus producing bacteria disruption of bacterial biofilms, and increasing the susceptibility to antibacterial treatment, for the management of respiratory diseases including, but not limited to, cystic fibrosis, chronic bronchitis, pulmonary emphysema, infectious pneumonia, chronic obstructive lung/pulmonary disease (COLD/COPD), tuberculosis, and fungal infection, to improve clearance of lung secretions by reducing their viscoelastic properties, reduce the frequency of respiratory infections and/or inflammation requiring parenteral antibiotics and/or anti-inflammatory drugs, respectively, and to improve pulmonary function, due to degradation of mucus produced by mucus producing bacteria in general and P. aeruginosa in particular. It is also recommended for the treatment of infected wounds and bums, ear and eye infections, urinary tract and other catheter associated infections.
- respiratory diseases including, but not limited to, cystic fibrosis, chronic bronchitis, pulmonary emphysema, infectious pneumonia,
- a method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent is effected by subjecting the surface protected bacteria to a glycosaminoglycans degrading enzyme.
- a method of rendering a surface protected bacteria less capable of adhering to a substratum is effected by subjecting the surface protected bacteria to a glycosaminoglycans degrading enzyme.
- a method of treating a disease for relieving disease associated symptoms effected by the administration a therapeutical composition including a glycosaminoglycans degrading enzyme.
- a therapeutic composition for treating a surface protected bacteria associated disease or symptoms comprising a glycosaminoglycans degrading enzyme and an antibiotic. Examples of antibiotics are given in the Examples section hereinunder.
- a bactericide composition effective in eliminating a surface protected bacteria.
- the bactericide composition includes a glycosaminoglycans degrading enzyme and a bactericide.
- glycosaminoglycans refers to polysaccharide-protein conjugates, such as, but not limited to, heparan sulfate, hyaluronic acid, chondroitin sulfate, keratan sulfate I, II, dermatan sulfate and heparin.
- surface protected bacteria refers to mucoid bacteria, alginate-producing bacteria and/or biofilm-producing bacteria.
- anti-bacterial agent refers to natural and man-made agents effective in killing and/or inhibiting the growth rate of bacteria.
- Anti-bacterial agents according to the present invention include bactericides, such as, but not limited to, biocide SDS, antibiotics and immune moieties, such as antibodies and immune cells, e.g., macrophages, T cells and the like.
- the glycosaminoglycans degrading enzyme according to the present invention can be of any type. It can be a lysosomal hydrolase or a bacterial lyase. It can be an endoglycosidase, an exoglycosidase or a sulfatase.
- heparanse connective tissue activating peptide III (CTAP), hyaluronidase, glucoronidase, iduronate sulfatase, heparinase I, heparinase II heparinase III, chondroitinase ABC, chondroitinase AC, chondroitinase B and/or chondroitinase C.
- CTAP connective tissue activating peptide III
- hyaluronidase hyaluronidase
- glucoronidase glucoronidase
- iduronate sulfatase heparinase I, heparinase II heparinase III
- chondroitinase ABC chondroitinase AC
- chondroitinase B chondroitinase C.
- the surface-protected bacteria according to the present invention can be of any genus capable of surface protection, including, but not limited to, Pseudomonas, Azotobacter, Azomonas, Serpens, Fusobacterium, Klebsiella, Streptococcus, Staphylococcus or Treponema. Pseudomonas aeruginosa which is known to cause pulmonary infection in CF patients is of particular interest.
- the method and composition according to the present invention is effective in treating lungs of patients suffering chronic pulmonary infection, associated, for example, with cystic fibrosis, for relieving symptoms associated therewith.
- Treating infected lungs according to the present invention is preferably effected by an inhaler device designed to generate an aerosol of the therapeutic composition according to the present invention.
- the present invention is also effective in treating other organs of the body and/or other conditions, such as, but not limited to, ears, eyes, teeth, gums, wounds and bums which can be infected by surface protected bacteria.
- treating when used in conjunction with a disease refers to substantially inhibiting, slowing or reversing the progression of a disease, substantially ameliorating clinical symptoms of a disease or substantially preventing the appearance of clinical symptoms of a disease.
- the glycosaminoglycans degrading enzyme according to the present invention can be formulated in a composition, which may include thickeners, carriers, buffers, diluents, surface active agents, preservatives, and the like, all as well known in the art.
- Pharmaceutical compositions may also include one or more active ingredients such as but not limited to anti inflammatory agents, anti microbial agents, anesthetics, bactericides, antibiotics and the like in addition to the glycosaminoglycans degrading enzyme.
- Other enzymes, such as DNase can also be included for some applications (e.g., treatment of CF lung).
- the pharmaceutical composition can be administered in either one or more of ways depending on whether local or systemic treatment is of choice, and on the area to be treated. Administration may be done topically (including ophtalmically, vaginally, rectally, intranasally), orally, by inhalation or parenterally.
- Formulations for topical administration may include but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and powders.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- Formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.
- Formulations for parenteral administration may include but are not limited to sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
- Dosing is dependent on severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with course of treatment lasting from several days to several months or until a cure is effected or a diminution of disease state is achieved. Persons ordinarily skilled in the art can easily determine optimum dosages, dosing methodologies and repetition rates.
- the method and bactericide composition according to the present invention are effective in inhibiting or killing surface protected bacteria growing on a non-living substratum, which forms, for example, a part of a medical device, such as, but not limited to, infusion device, a catheter device, a contact lens device, a dialysis device and a draining device.
- a medical device such as, but not limited to, infusion device, a catheter device, a contact lens device, a dialysis device and a draining device.
- the present invention successfully addresses the shortcomings of the presently known configurations by providing new means to combat surface protected bacteria (e.g., mucoid-, alginate-, biofilm-producing bacteria), which is effected by subjecting such bacteria to GAG degrading enzyme, rendering such bacteria surface non-protected and susceptible to anti-bacterial agents and less capable of adhering to various substrata.
- surface protected bacteria e.g., mucoid-, alginate-, biofilm-producing bacteria
- glycosaminoglycans degrading enzymes such as, but not limited to, heparanases, connective tissue activating peptide, heparinases, glucoronidases, heparitinases, hyaluronidases, sulfatases and chondroitinases are used, alone, in combination, or in combination with conventional substances, preferably as aerosol, for the management of diseases associated with infection by surface protected bacteria.
- glycosaminoglycans degrading enzymes on the amounts of bacterial alginate production and the associated payoffs, in addition to their effects on reducing the viscosity of sinuses and airway secretions with associated implications derived from cellular heparan sulfate degradation on curtailing the rate of infection and inflammatory responses (see U.S. patent application Ser. No. 09/046,475), will result in reduction and/or prevention of chronic infection, reduction of tissue damage, thus improving the patients quality of life and prolong life span.
- Bacterial strain Clinical isolates of a mucoid Pseudomonas aeruginosa strains from CF patients were kindly provided by Dr. H Berkovier from the Hadassa hospital, Ein Kerem, and Prof. E. Kerem from Shaarei Tsedek hospital, Jerusalem. Bacteria were grown on either McConkey agar plates (Hi Labs, Israel), or tryptic soy broth (TSB)+1.5% agar (Difco) or 1.5% agarose (FMC BioProducts, USA) plates, or in tryptic soy broth (Difco Laboratories, USA).
- Monosaccharide composition of P. aeruginosa alginate Monosaccharide composition of P. aeruginosa alginate was tested using FACE Glycosaminoglycan Identification Kit (Glyco, Inc., Novato, Calif., USA), according to manufacture's instructions.
- TSB+1.5% agar or 1.5% agarose plates were prepared according to manufactures instructions. Plates were covered with mucoid P. aeruginosa isolate using a cotton swab. Whatman's 25 mm 3 MM discs were then placed on the seeded bacteria.
- the discs were loaded with either 50 ⁇ l 0.1 ⁇ g/ ⁇ l recombinant human heparanase, or 50 ⁇ l 0.1 ⁇ g/ ⁇ l heat inactivated (10 min at 100° C.) recombinant human heparanase, or 50 ⁇ l heparanase buffer (10 mM buffer phosphate pH 6.8, 0.4 M NaCl, with or without 1 mM DTT), or 25 ⁇ l (3 units/ ⁇ l) hyaluronidase (Sigma), or 25 ⁇ l heparinase II (0.01 unit/ ⁇ l) (kindly provided by Prof. I.
- a bacterial colony was collected with a sterile tip and suspended in 500 ⁇ l saline. Fifty ⁇ l were added to a culture medium containing 50% TSB, 50% saline, 20 mM citrate-phosphate buffer pH 5.6 with either heparanase 2.5 ⁇ g/ml (50 ⁇ l), or 50 ⁇ l boiled heparanase, or 50 ⁇ l heparanase buffer. Culture was shaken 18 hours at 37° C. A sample from each tube was recultured on a TS agar plate and incubated at 37° C., 18 hours, and the cultures phenotype was recorded. 0.5 ml from each tube was sampled for viscosity testing, using microviscosometer (Haake, W. Germany).
- Antibiotic susceptibility test discs The enzyme-treated discs were tapped with a coffon swab that was then used to seed the “treated” bacteria onto a new TS plate. Susceptibility discs were then placed on the seeded plates and incubated for 18 hours at 37° C. The zone of inhibition of bacterial growth was measured with a ruler.
- MIC The minimal inhibitory concentration (MIC) was determined by serial dilutions of various types of antibiotics (Enrofloxacin, sulfa/trimethoprim, gentamycin and amikacin), for various P. aeruginosa isolates obtained.
- Watmann's 3 MM disc were used following the concept of susceptibility discs.
- the discs were placed on a TS agar plate that was previously seeded with P. aeruginosa isolate No. 1.
- heparanase, heparinase II and chondroitinase ABC induce phenotypic changes of mucoid P. aeruginosa, exhibiting a reduced amount of alginate, slower proliferation rate and higher susceptibility to a wide range of antibiotics.
- the enzymes degrade the alginate; (ii) the enzymes interfere with alginate production; (iii) the enzymes interfere with intercellular signaling for alginate production or alginate degradation by lyases; (iv) the enzymes inhibit bacterial proliferation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Anesthesiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This is a continuation in part of U.S. patent application Ser. No. 09/046,475, filed Mar. 25, 1998, which is a continuation-in-part of U.S. patent application Ser. No. 08/922,170, filed Sep. 2, 1997.
- The present invention relates to the use of glycosaminoglycans degrading enzymes, such as, but not limited to, heparanases, connective tissue activating peptide III (CTAP), heparinases, hyaluronidases and chondroitinases, against surface protected bacteria, for reduction of bacterial alginate and for the disruption of bacterial biofilms. More particularly, the present invention relates to the use of glycosaminoglycans degrading enzymes for treating conditions resulting from infection by mucoid, alginate-producing and/or biofilm-producing bacteria.
- Glycosaminoglycans degrading enzymes: Glycosaminoglycans (GAG) are unbranched polyanionic polysaccharides made up of repeating disaccharides. One component of which is always an amino sugar. Degradation of GAG is carried out by a battery of lysosomal hydrolases. These include certain endoglycosidases (heparanse and CTAP degrade heparan sulfate and to a lesser extent heparin, and hyaluronidase from sheep or bovine testes degrade hyaluronic acid and chondroitin sulfate), various exoglycosidases (β-glucoronidase), and sulfatases (iduronate sulfatase), generally acting in sequence to degrade the various GAG. Bacterial lyases such as heparinase I, II and III fromFlavobacterium heparinum cleave heparin-like molecules, chondroitinase ABC from Proteus vulgaris, AC from Arthrobacter aurescens or Flavobacterium heparinum, B and C from Flavobacterium heparinum degrade chondroitin-sulfate.
- Bergey's Manual of Determinative Bacteriology describes 149 species of the genus Pseudomonas. However as with species designations in other groups of organisms, many are based on minor points of difference, which may vary under different conditions of growth and nutrition. Most species are motile with polar flagella: straight rods or occasionally coccoid in shape. They grow well on conventional culture media, and many strains thereof produce characteristic pigmentation. All species exceptP. maltophilia are recognized as having a cytochrome C oxidase present when tested with tetramethyl-p-phenylenediamine, a characteristic that distinguishes them from the enterobacteroaceae. Although Pseudomonas are not particularly invasive, once they are established as infective agents, they are very difficult to eradicate (Handbook of Microbiology, Vol. 1 1974 pp. 239-242).
-
- The pathogenicity of mucoidP. aeruginosa in the CF lung is attributed in part to the synthesis of the exopolysaccharide alginate by the bacterium. Nonmucoid strains of P. aeruginosa initially colonize the upper respiratory tract of CF patients. However, mucoid alginate-producing variants appear with prolonged infection and eventually predominate in the CF lung. The alginate produced by these mucoid strains of P. aeuriginosa compounds the problems related to the hyperviscous bronchial secretions of CF patients. Alginate-producing strains of P. aeruginosa are almost exclusively associated with respiratory tract infections that accompany CF. Although 80% of the P. aeruginosa isolates form CF patients are mucoid, only about 1% of clinical P. aeruginosa isolates from other types of infections are mucoid. Alginate appears to protect P. aeruginasa by shielding it from host immune defense and antibiotic therapy, and possibly enables it to adhere more effectively to respiratory tract tissues. Once established in the CF lung, these mucoid strains tend to persist and parallel the progressive clinical deterioration of the patient. Alginate is a linear acetylated copolymer consisting of β-1,4-linked D-mannuronic acid and variable amounts of its C-5 epimer L-guluronic acid. Alginate is produced by several bacterial species, the most widely known being Azotobacter vinelandii and P. aeruginosa. Bacterial alginates differ from algal alginate in that the former contain O-acetyl groups. The viscosity level of alginate may play a role in the pathogenesis of mucoid P. aeruginosa in the CF respiratory tract. Several enzymes are involved in the alginate biosynthetic pathway: Phosphomannose isomerase (PMI), GDP-mannose dehydrogenase (GMD), and GDP-mannose pyrophosphorylase (GMP) in mucoid, alginate-producing P. aeruginose. Activities of the enzymes are either absent or greatly reduced in nonmucoid strains.
- Alginate synthesis by the highly mucoidP. aeruginosa 8821 M is growth-phase-dependent and the alginate produced per unit of biomass reaches maximum values in the deceleration phase of growth. However, the degree of polymerization increases as batch growth proceeds, reaching maximum values at the stationary phase of growth (Leitao J H, Sa-Correia I; Arch Microbiol March 1995; 163(3): 217-222).
- Regulation of alginate synthesis: The regulation of alginate biosynthesis byP. aeruginosa appears to involve fine tuning of several factors. A pivotal step in alginate biosynthesis is the activation of the algD gene in mucoid, alginate-producing P. aeruginosa . algD is highly activated in response to increased concentrations of either KCl or NaCl. This is an interesting finding since the CF lung is rich in Na+, Cl− and K+ ions.
- Alginate-producing strains of three other Pseudomonas species (P. fluorescens, P. putida, and P. mendocina) have been isolated in vitro by growth on subinhibitory concentrations of carbenicillin. Also, certain phytopathogen Pseudomonas species produce alginate both in planta and in vitro. These observations suggest that many species of Pseudomonas harbor genes involved in alginate biosynthesis, but that they are not normally expressed. Since many of the P. aeruginosa alginate genes had been cloned, it was possible to examine genomic DNA from various Pseudomonas species and phylogenetically related organisms for sequences homologous to the P. aeruginosa alg genes. Southern hybridization studies using algA, pmm, algD, and algR1 as probes showed some degree of homology with several Pseudomonas species belonging to Pseudomonas RNA
homology group 1. Some probes also hybridized with Azotobacter, Azomonas, and Serpens species. In the laboratory, the alginate-producing (alg+) phenotype is somewhat unstable, and nonmucoid (alg−) revertants are commonly seen. Genetic mapping experiments have shown that the switching between alg+ and alg− is due to a genetic change in one region of the chromosome located at about 68 min on the 75-min chromosomal linkage map of Pseudomonas. This was originally referred to as the muc locus. Two additional recognized genes are involved in the regulation of alginate production. These are algR at 9 min and algB at 13 min, both of which are required for high-level alginate production. However, most of the alginate biosynthetic genes appear to be located in a larger gene cluster at 34 min. - Collectively, the regulation of the alginate biosynthetic pathway inP. aeruginosa is multignenic and appears to be relatively complex, which suggests that this system has a long evolutionary history. Alginate is secreted in copious amounts (e.g., 2 mg/ml in culture supernatants), thus channeling much of the available carbon and energy sources toward its production. It is not surprising that alginate biosynthesis would be tightly regulated. However, when production of alginate is advantageous to the organism (such as in the CF respiratory tract) the rare mucoid cells in the population become predominant because of their selective advantage. When alginate production is no longer advantageous, the instability of the Alg+ phenotype (controlled by the genetic switch algS) allows the nonmucoid population to quickly become predominant as a result of the ability to conserve carbon and energy resources. Environmental factors may also play a role in the frequency of alginate conversion. Because virtually all CF isolates of P. aeruginosa are mucoid, it was postulated that the lung environment of CF patients provides the trigger required to turn on the production of the alginate adhesin. To identify virulence genes of P. aeruginosa that are important in infection of CF patients, an in vivo selection system (IVST) was used to identify promoters that are specifically inducible by respiratory mucus derived from CF patients. Three genetic loci that are highly inducible by the mucus were identified (Wang J et al.; Mol Microbiol December 1996; 22(5): 1005-12).
- It is unlikely that this complex regulatory scheme to activate alginate production evolved solely as a pathogenic mechanism specific for the infection of CF patients.P. aeruginosa normally dwells in the soil environment, and alginate conversion may have evolved to protect the bacterial population from destruction due to attack by bacteriophages or bactriocins or from desiccate during periods of dryness. However, P. aeruginosa is a remarkable opportunistic pathogen and has adapted the alginate conversion system to promote debilitating and life threatening pulmonary infections of CF patients. Understanding alginate gene regulation in P. aeruginosa may lead to treatments that could turn off alginate production by the organisms resident in the CF lung, thus improving the longevity and quality of life for these patients (Pseudomonas: biotransformations, pathogenesis, and evolving biotechnology. Edited by Simon Silver et al., 1990 Am. Soc. For Microbiol. Ch. 2 and 3, pp. 15-36)
- Adhesion mechanisms ofP. aeruginosa: Adherence through carbohydrate-binding adhesins is an early step in colonization of the lung by gram-negative organisms (Azghani AO et al.; Glycobiology February 1995; 5(1): 39-44). Pseusomonas aeruginosa is an opportunistic pathogen capable of causing serious localized infections of the cerebrospinal fluid (CSF), urinary tract, eye, ear, lung, skin, and other parts of the body. The organism is often isolated from peritoneal dialysis membranes. Generalized systemic infections tend to occur only in injured, immunodeficient, or otherwise compromised patients. It is not surprising, therefore, that this genus has developed a number of adhesion mechanisms, each being specific for a particular type of substratum. There are numerous articles reporting various mechanisms of adhesion for P. aeruginosa. These include the hydrophobic effect, adhesion to and by alginates, and lectin-dependent adhesion. Some reports maintain that the adhesion of P. aeruginosa is fimbriae-dependent. The exopolysaccharide alginate binds to buccal epithelial and tracheal cells, as well as to bronchotracheal mucin. Antipolysaccharide inhibits binding of the organisms to the tracheal cells. Also, mucoid strains of Pseudomonas adhere much better to tracheal cells compared to nonmucoid strains or compared to alginate-producing bacteria grown in an antibiotic medium to reduce alginate production. Alginate appears to play a role in the adhesion of Pseudomonas to contact lenses. Microscopic evidence suggests that mucoid strains may adhere to ciliated tracheal cells and to inert surfaces, including contact lenses, by polysaccharide-like materials. The presence of alginate in the reaction mixture causes an increase in the number of bacteria adherent to tracheal cells or immobilized mucin. It has been suggested that the alginate may act to trap and tether the organisms to the substrata, thereby allowing other adhesins, such as the fimbrial adhesin complex, to bind the specific receptors. If the target animal cell or substrata lacks the ability to bind alginate, then the presence of an exopolysaccharide coat on the bacterial surface may actually impede the ability of the organisms to attach to such animal cells. This may explain the rescued ability of the mucoid strains to bind to phagocytic cells or to primary cultures of cilliated epithelial cells. The phagocytic cells lack the ability to bind alginate.
- There are several reports showing that adhesion ofP. aeruginosa to various substrata may involve lectins specific for carbohydrates other than sialic acid. For example, adhesion of the bacteria to the tracheal epithelium is inhibited by D-galactose and N-acetyl-D-glucosamine. Moreover, putative nonfimbrial adhesins produced by both mucoid and nonmucoid strains of Pseudomonas, specific for Galβ1, 4GlcNAc or Galβ1, 3GlcNAc sequences, may be involved in mediating binding of the organisms to human bronchial mucins (Bacterial Adhesion to Cells and Tissues/Ofek I and Doyle R J, 1994 Chapman & Hall, Inc. pp. 114-116, 418-421).
-
- It was shown that in continuous flow biofilm cultures in medium resembling CF bronchial secretions,P. aeruginosa was not eradicated form biofilms by 1 week of treatment with high concentrations of ceftazidime and gentamicin, to which they are sensitive on conventional testing. The addition of rifampicin, which has little activity against the strains as measured by the minimum inhibitory concentration, led to the apparent elimination of the bacteria from the biofilms. The effect was not strain specific. Ghani M and Soothill J S; Can J microbial November 1997; 43(11): 999-1004.
- Scanning electron microscopy (SEM) showed that the internal surfaces of catheters and drainage systems are commonly colonized by thick layers or biofilms of organisms embedded in a polysaccharide matrix. There is evidence from laboratory and clinical studies that the progressive spread of the biofilm along the luminal surfaces of the bag, tube and catheter leads to bladder infection (Stickler D J et al.; Br J Urol. 1996, 78; 579-88).
- Biofilms are also an integral part of dental plaque, thereby contributing to tooth decay and periodontal disease. One target isFusobacterium nucleatum, an oral bacteria found in biofilms coating the area between teeth and gums (Potera C; ASM News, 64(6), 1998).
- The incidence of gram-negative bacteria in reviews of postoperative acute endophthalmitis ranges from 3-22% withP. aeruginosa being one of the more common etiological agents of fulminant infections. These infections usually develop within days of the surgery and have a poor prognosis. P. aeruginosa has been reported to adhere to damaged corneal cells as well as to contact lenses. Its adherence to silicone and latex materials is significantly greater that of several isolates of Staph. Epidermidis. The in vitro adherence of P. aeruginosa to a variety of hydrogel and rigid gas-permeable contact lenses correlates with clinical data. P. aeruginosa adheres to the optic material of intraoccular lenses: AcrySof-acrylic<PMMA<
silicone 1<silicon 2, and form biofilms (Manal M et al.; J Cataract Refract Surg vol. 24, January 1998). - CF lung predilection for excessive inflammation and infection withP. aeruginosa: In CF, defective function of the CFTR in airway epithelial cells and submucosal glands, results in chronic pulmonary infection with P. aeruginosa. The pulmonary infection incites an intense host inflammatory response, causing progressive suppurative pulmonary disease. Several hypotheses have been proposed to explain CF lung predilection for excessive inflammation and infection with P. aeruginosa.
- The role of alginate in pathogenesis is complex and appears to confer antiphagocytic properties and an adherence mechanism upon the organism. Autopsies show that mucoidP. aeruginosa forms adherent microcolonies in the lung. Alginate does not firmly adhere to the organisms but is released in large quantities into the respiratory environment. Because alginate is very viscous in aqueous solution, it probably contributes to the high viscosity of the bronchial secretions in the CF lung, resulting in obstruction of small airways, interference with mucociliary airway clearance, and impaired movement to phagocytes. The mucoid organisms may be more adapted to a chronic infection because they secrete lower levels of proteases, which would otherwise cause extensive lung damage and acute infection. Also P. aeuruginosa can utilize the respiratory secretions of the CF lung to support rapid growth and alginate biosynthesis; thus, the mucus-congested CF respiratory tract provides P. aeruginosa with a nutritionally rich environment favorable to clonization. The initial colonization of the CF upper respiratory tract appears to be with a nonmucoid strain and is often asympomatic. This usually precedes the emergence of mucoid variants of the original strain and is followed by chronic infection and a poor prognosis for the patient.
- CF patients do produce opsonic antibodies to mucoidP. aeruginosa that are in a planktonic or suspended state, but these antibodies fail to kill P. aeruginosa growing in a biofilm (Pier G B; Behring Inst Mitt February 1997; 98: 350-60). Results showed that alginate and neutral polysaccharides are involved in phagocytic impairment of P. aeruginosa (Pasquier C et al.; FEMS Microbiol Lett Feb. 15, 1997; 147(2): 195-202). Alginate production inhibits opsonic and nonopsonic phagocytosis, protects cells form reactive oxygen intermediates and plays additional roles associated with biofilm phenomena (Hatano K et al.; Infect Immun. January 1995; 63(1): 21-26; Meluleni G J et al.; J. Immunol. Aug. 15, 1995; 155(4): 2029-38). The results support the findings of the previous extensive work carried out in vitro, suggesting that the phagocytic and other bactericidal systems in the lung are impaired: Some investigators suggest that the elevated salt content in the surface fluid of the CF airway renders human β-defensin-1 nonfunctional, eliminating the bactericidal activity of the respiratory epithelium. Another hypothesis suggests that failure of the respiratory epithelial cells in the CF lung to ingest bacteria and be sloughed allows for P. aeruginosa retention at the endobronchial surface. The airway epithelial cell ingestion of bacteria followed by cellular desquamation may protect the lung form infection, and epithelial cells expressing mutant forms of the CFTR may be defective in this function. It was found that transformed human airway epithelial cells homozygous for the delta F508 allele of CFTR were significantly defective in uptake of P. aeruginosa compared with the same cell line complemented with the wild-type allele of CFTR. Defective epithelial cell internalization of P. aeruginosa may be a critical factor in hyper susceptibility of CF patients to chronic lung infections (Pier G B et al.; Am J Respir Crit Care Med October 1996; 154(4 Pt 2): S175-82; Proc Natl Acad Sci U S A Oct. 28, 1997; 94(22): 12088-93). The majority of CF mucoid isolates carry mucA mutations which allow transcription of alginate biosynthetic genes, resulting in a mucoid phenotype. Mucoidy is caused by muc mutations that depress the alternative sigma factor encoded by algU, which in turn activates alginate biosynthetic and ancillary regulatory genes (Boucher J C et al.; Infec Immun September 1997; 65: 3838-46; Boucher J C et al.; J Bacteriol January 1996; 178(2): 511-23). Mucoid cells are cleared less efficiently and appears to linger in the lung longer that nonmucoid organisms. This finding suggests that mucoidy may confer an ability to resist innate clearance mechanisms in the lung and, along with other potentially contributing factors, could be the basis for selection of mucA mutants in CF (Yu H et al.; Infec and Immun. 1998, 66(1): 280-88). Another possibility is that Pseudomonas adheres to epithelial cells in the CF airway in greater numbers because of the abnormal surface properties of the cells, thus leading to infection.
- Although details of the mechanism differ, all of these hypotheses predict that the basic defect in CF permits retention of bacteria at an otherwise sterile site, providing the stimulus for inflammation. Furthermore, it is suggested that the CF genotype is associated with excessive inflammatory response compared with the normal response, even if the initiating stimulus is similar. In order to understand the pathogenesis of pulmonary disease characteristic of CF, it is required to examine not only the impaired clearance of the bacteria, but also the excessive host response toP. aeruginosa (Van Heeckeren A et al.; J. Clin Inves. December 1997; 100(11): 2810-5).
- Thus,P. aeruginosa is a remarkable opportunistic pathogen and has adapted the alginate conversion system to promote debilitating and life threatening pulmonary infections of CF patients. The environment of the CF lung is unique in its capacity to induce alginate production by P. aeruginosa. However, the factors which contribute to this unusual host-pathogen interaction have not yet been determined.
- Understanding alginate gene regulation inP. aeruginosa may lead to treatments that could turn off alginate production by the organisms resident in the CF lung, thus improving the longevity and quality of life for these patients.
- CF is the most common fatal genetic disease among the Caucasian population, affecting approximately 1:2500 newborns. The median age of survival of patients with CF has dramatically increased over the past 2 decades from less than 10 to more than 30 years. This progress has occurred primarily through improved nutritional support and aggressive management with antibiotic therapy of acute pulmonary infections. Currently there is no effective combination of therapies which completely eradicates alginate-producingP. aeruginosa from the CF lung environment. The development of new compounds effective in preventing alginate synthesis represents a major step towards reaching this goal. Such inhibitors of alginate synthesis have potential clinical applications in that elimination of the alginate capsule might render P. aeruginosa more susceptible to both antibiotic therapy and the host's immune system. Therefore, many laboratories are involved in an extensive study of the genetics and regulation of the alginate biosynthetic pathway in P. aeruginosa in an effort to identify factors unique to the CF lung environment that trigger expression of the genes involved in alginate biosynthesis and in an attempt to find nontoxic compounds that inhibit alginate synthesis by inhibiting the enzymes directly involved in the pathway.
- Mrnsy R J et al. have investigated the use of an alginate lyase obtained from a bacterial source to disruptP. aeruginosa alginate's polymeric nature and effect a change in the Theological properties of CF sputum in vitro. Their results suggested that bacterial alginate present within purulent CF sputum may be quite stable, that endogenous alginate lyase activities appear to be limited and that the in vitro addition of exogenous alginate lyase can lead to the disruption of alginate and a change in the viscoelastic properties of some purulent CF sputum samples (Mrsny R J et al.; Pulm Pharmacol December 1994; 7(6): 357-66).
- A suspension of 2%P. aeruginosa alginate completely blocked the diffusion of gentamycin and tobramycin, but not that of carbenicillin, illustrating how alginate production can help protect P. aeruginosa growing within alginate microcolonies in patients with CF from the effects of aminoglycosides. This aminoglycoside diffusion barrier was degraded with a semipurified preparation of P. aeruginosa alginate lyase (Hatch R A, Schiller N L; Antimicrob Agents Chemother. April 1998; 42(4): 974-7).
- A 41 kDa alginate lyase capable of degrading alginic acid ofP. aeruginosa was prepared from the culture of Bacillus strain ATB-1015. The enzyme was found useful for the treatment of respiratory diseases caused by infection by P. aeruginosa (JP 95-181047, JP 09009962 A2 to Akira Nakagawa). Alginic acid lyase(s) which decompose alginic acid into sugar and the 4-deoxy-5-keto uronic acid is used for treatment of pulmonary cystic fibrosis (JP 06197760 A to Yakuhin Otsuka). However, these lyases fail to degrade glycosaminoglycans.
- More therapeutic approaches: Phagocytosis ofP. aeruginosa by macrophages is a unique two-step process; binding is glucose-independent but ingestion occurs only in the presence of D-glucose or D-mannose. Since glucose is present in only negligible quantities in the endobroncheal space, P. aeruginosa may be pathogenic by virtue of its capacity to exploit the opportunity presented in the lower airway to resist normal nonspecific phagocytic defenses. Because delivery of simple glucose by aerosol would not be effective, various approaches for targeting glucose to alvelolar macrophages by receptor-mediated endocytosis are under investigation (Speert D P et al.; Behring Inst Mitt February 1997; 98: 274-82).
- The ongoing lung tissue damage in chronicallyP. aeruginosa infected CF patients has been shown to be caused by elastase liberated from polymorphonuclear leukocytes (PMN). Alginate alone appeared to be a weak inhibitor of the hydrolysis of long synthetic peptide substrates and [14C]elastin by elastase. Alginate also had effects on the antielastase function of naturally occurring protease inhibitors in the lung: It reduces the association rate of elastase and alpha 1-proteinase inhibitor, whereas it increases the association rate of elastase and secretory leukoprotease inhibitor.
- Based on these finding, alginate may be an important factor in determining the local distribution of leukocyte elastase and perturbing the overall protease-antiprotease balance in the infected lungs of CF patients (Ying Q L et al.; Am j Respir Cell Mol Biol. August 1996; 15(2): 283-91).
- Thus, prevention of the onset of the chronic infection or prevention of the dominance of the inflammation by PMNs would be important goals for a vaccine strategy againstP. aeruginosa. Findings suggested that change from the Th2 like response seen in CF patients towards a Th1 response might improve their prognosis (Johansen H K et al.; Behring Inst Mitt February 1997; 98: 269-73).
- Care should be taken when treating nonmucoidP. aeruginosa with gyrase inhibitors such as ciprofloxacin, norfloxacin and ofloxacin, which target the A subunit of topoisomerase II, since it resulted in 100% conversion to the mucoid phenotype. An increase in resistance was observed in populations that expressed the mucoid phenotype. Both mucoid conversion and antibiotic resistance were completely reversible when ciprofloxacin pressure was withdrawn, but only partially reversible by the removal of norfloxacin and ofloxacin. Thus, these experiments indicate that in the presence of some fluoroquinolones, a conditional response resulting in mucoid conversion and antibiotic resistance may occur (Pina S E, Mattingly S J; Curr Microbiol August 1997; 35(2): 103-8).
- Other mucoid bacteria:Klebsiella Pneumoniae K1 synthesizes capsular polysaccharide. Non mucoid variants thereof are more susceptible to some bacteriophages, possibly due to the reduction or absence of capsular polysaccharide (Mengistu Y et al.; J Appl Bacteriol May 1994, 76(5): 424-30). There are two virulence factors of K. pneumoniae: aerobactin and the mucoid phenotype. Aerobactin is always associated with the mucoid phenotype (FEMS Microbiol Lett. Jul. 15, 1995; 130(1): 51-57).
- Mucoid or highly encapsulated strains of group A Streptococci have been associated both with unusually sever infections and with acute rheumatic fever. The mucoid M-type 18 strain of a group A Streptococcus has a hyaluronic acid capsule which plays an important role in virulence. The region of the chromosome essential for capsular polysaccharide expression is conserved among diverse group A streptococcal strains. Wessels M R et al.; Infec Immun February 1994; 62(2): 433-41. In communities, where increases in cases of rheumatic fever had been reported, the serotypes M-1, 3, 5, and 18 were isolated which, on culture, produced characteristic mucoid colonies (Spencer R C; Eur J Clin Microbiol Infect Dis. 1995, 14 Suppl 1: S26-32). The
mucoid serotype 3 of S. pneumoniae cause rapid fatal infections, despite adequate antibiotic therapy (Hsueh P R et al.; J Formaos Med Assoc May 1996; 95(5): 364-71). - The antiphagocytic effect of M protein has been considered a critical element in virulence of the group A Streptococcus. The hyaluronic acid capsule also appeared to play an important role: studies of an acapsular mutant derived form the mucoid or highly encapsulated M protein type 18 group A strepococcal strain 282 indicated that loss of capsule expression was associated with decreased resistance to phagocytic killing and with reduced virulence in mice. The results provide further evidence that the hyaluronic acid capsule confers resistance to phagocytosis and enhances group A streptococcal virulence. Moses A E et al.; Infect Immun. January 1997; 65(1): 64-71.
- Staphylococcus aureus arthritis is a rapidly progressive and highly erosive disease of the joints in which both host and bacterial factors are of pathogenic importance. One potential bacterial virulence factor is the ability to express a polysaccharide capsule (CP). Among 11 reported capsular serotypes, CP type 5 (CP5) and CP8 comprise 80-85% of all clinical blood isolates. The results clearly indicated that the expression of CP5 is a determinant of the virulence ofS. aureus in arthritis and septicemia (Nilsson I M et al.;
Infec Immun 1 October; 65(10): 4216-21). -
- The above described data implies that there is a widely recognized need for, and it would be highly advantageous to have agents effective in reducing mucus production by bacteria, by, for example, degradation or prevention of synthesis of the bacterial exopolysaccharide alginate. The benefits from employing such agents for the degradation of bacterial exopolysaccharide alginate include (i) viscosity reduction of alginate related hyperviscous bronchial secretions; (ii) disruption of bacterial biofilms which may render the bacteria more susceptible to host immune defense systems and antibiotic therapy; (iii) inhibition of alginate associated adhesion to host cells and enhancement of bacterial clearance, resulting in reduction of infection rate; (vi) reduction of host's inflammatory response to infection.
- According to one aspect of the present invention there is provided a method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent comprising the step of subjecting the bacteria to a glycosaminoglycans degrading enzyme.
- According to another aspect of the present invention there is provided a method of rendering a surface protected bacteria less capable of adhering to a substratum comprising the step of subjecting the bacteria to a glycosaminoglycans degrading enzyme.
- According to yet another aspect of the present invention there is provided a method of treating a disease for relieving disease associated symptoms comprising the step of administering a therapeutical composition including a glycosaminoglycans degrading enzyme.
- According to still another aspect of the present invention there is provided a therapeutic composition for treating a surface protected bacteria associated disease or symptoms comprising a glycosaminoglycans degrading enzyme and an antibiotic.
- According to yet another aspect of the present invention there is provided a bactericide composition effective in eliminating a surface protected bacteria comprising a glycosaminoglycans degrading enzyme and a bactericide.
- According to further features in preferred embodiments of the invention described below, the surface protected bacteria is a mucoid bacteria.
- According to still further features in the described preferred embodiments the surface protected bacteria is an alginate-producing bacteria.
- According to still further features in the described preferred embodiments the surface protected bacteria is a biofilm-producing bacteria.
- According to still further features in the described preferred embodiments the anti-bacterial agent is a bactericide.
- According to still further features in the described preferred embodiments the anti-bacterial agent is an antibiotic.
- According to still further features in the described preferred embodiments the anti-bacterial agent is an immune moiety.
- According to still further features in the described preferred embodiments the glycosaminoglycans degrading enzyme is selected from the group consisting of a lysosomal hydrolase and a bacterial lyase.
- According to still further features in the described preferred embodiments the glycosaminoglycans degrading enzyme is selected from the group consisting of an endoglycosidase, an exoglycosidase and a sulfatase.
- According to still further features in the described preferred embodiments the glycosaminoglycans degrading enzyme is selected from the group consisting of heparanse, connective tissue activating peptide III (CTAP), hyaluronidase, glucoronidase, iduronate sulfatase, heparinase I, heparinase II heparinase III, chondroitinase ABC, chondroitinase AC, chondroitinase B and chondroitinase C.
- According to still further features in the described preferred embodiments the bacteria is of a genus selected from the group consisting of Pseudomonas, Azotobacter, Azomonas, Serpens, Fusobacterium, Klebsiella, Streptococcus, Staphylococcus and Treponema
- According to still further features in the described preferred embodiments the bacteria is of a genus Pseudomonas
- According to still further features in the described preferred embodiments the bacteria isPseudomonas aeruginosa
- According to still further features in the described preferred embodiments the bacteria is in a lung of a patient suffering chronic pulmonary infection, the method being for relieving symptoms associated with the chronic pulmonary infection.
- According to still further features in the described preferred embodiments the bacteria is in a lung of a cystic fibrosis patient suffering chronic pulmonary infection, the method being for relieving symptoms associated with the chronic pulmonary infection.
- According to still further features in the described preferred embodiments the bacteria is growing on a non-living substratum.
- According to still further features in the described preferred embodiments the non-living substratum forms a part of a medical device.
- According to still further features in the described preferred embodiments the medical device is selected from the group consisting of an infusion device, a catheter device, a contact lens device, a dialysis device and a draining device.
- The present invention successfully addresses the shortcomings of the presently known configurations by providing methods and compositions effective in combating surface protected bacteria (e.g., mucoid-, alginate-, biofilm-producing bacteria), by subjecting such bacteria to glycosaminoglycans degrading enzyme, rendering such bacteria surface non-protected and therefore more susceptible to anti-bacterial agents and less capable of adhering to various living and non-living substrata.
- The invention herein described, by way of example only, with reference to the accompanying drawings, wherein:
- FIG. 1 demonstrates the monosaccharide composition of mucoidP. aeruginosa isolate No. 1 (
samples 11, 12) and of three sputum samples from CF patients (samples - FIGS. 2a-e demonstrate the effect of heparanase on the amount of mucus produced by mucoid P. aeruginosa isolate No. 1. Bacteria were plated on tryptic soy agar (2 a-d) or McConkey agar (2 e). Discs soaked with the examined compound were placed on top. E=heparanase, I=boiled heparanase, B=heparanase buffer, C=chondroitinase ABC, C-I=boiled chondroitinase, D=DNase, D-I=boiled Dnase, Hy=hyaluronidase, H-II=heparinase II.
- FIGS. 3a-b demonstrate the effect of heparanase on sensitivity to antibiotics. (2 a) Bacteria were plated on tryptic soy agar following treatment with (from left to right, top to bottom) heparanase buffer, heparanase, boiled heparanase, chondroitinase ABC, hyaluronidase or heparinase II. Antibiotic discs were placed according to the scheme in FIG. 3b.
- FIGS. 4a-e demonstrate the effect of heparanase on mucoid P. aeruginosa isolate No. 40 proliferation rate and sensitivity to antibiotics. (4 a) The proliferation rate following treatment with I=boiled heparanase, E=heparanase, H-II=heparinase II, Hy=hyaluronidase. (4 b-e) The proliferation rate as in FIG. 4a, in the presence of antibiotics, (4 b) amikacin at MIC-2 (0.78 μg/ml); (4 c) amikacin at MIC-1 (1.56 μg/ml); (4 d) gentamycin at MIC-2 (0.39 μg/ml); (4 e) gentamycin at MIC-1 (0.78 μg/ml).
- The present invention is of methods and compositions effective in combating mucoid, alginate-producing and/or biofilm-producing bacteria, by subjecting such bacteria to glycosaminoglycans degrading enzymes, which can be used, for example, to treat infections caused by such virulent bacteria. Specifically, the present invention can be used for the reduction of mucus production by mucoidP. aeruginosa and other mucus producing bacteria, disruption of bacterial biofilms, and increasing the susceptibility to antibacterial treatment, for the management of respiratory diseases including, but not limited to, cystic fibrosis, chronic bronchitis, pulmonary emphysema, infectious pneumonia, chronic obstructive lung/pulmonary disease (COLD/COPD), tuberculosis, and fungal infection, to improve clearance of lung secretions by reducing their viscoelastic properties, reduce the frequency of respiratory infections and/or inflammation requiring parenteral antibiotics and/or anti-inflammatory drugs, respectively, and to improve pulmonary function, due to degradation of mucus produced by mucus producing bacteria in general and P. aeruginosa in particular. It is also recommended for the treatment of infected wounds and bums, ear and eye infections, urinary tract and other catheter associated infections.
- The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.
- Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
- U.S. patent application Ser. Nos. 08/922,170 and 09/109,386, which are incorporated by reference as if fully set forth herein teach the cloning of the heparanase gene. U.S. patent application Ser. No. 09/071,618, filed May 1, 1998, which is incorporated by reference as if fully set forth herein, teaches the production of recombinant heparanase by a variety of heterologous expression systems and the purification of recombinant heparanase. U.S. patent application Ser. No. 09/046,475, which is incorporated by reference as if fully set forth herein, teaches the use of glycosaminoglycans degrading enzymes for the management, treatment and relieve of symptoms of respiratory diseases associate with accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans. The present invention, on the other hand, relates to the use of glycosaminoglycans degrading enzymes to combat mucoid-, alginate- and/or biofilm-producing bacteria.
- Thus, according to one aspect of the present invention there is provided a method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent. The method is effected by subjecting the surface protected bacteria to a glycosaminoglycans degrading enzyme.
- According to another aspect of the present invention there is provided a method of rendering a surface protected bacteria less capable of adhering to a substratum. Again, the method is effected by subjecting the surface protected bacteria to a glycosaminoglycans degrading enzyme.
- Further in accordance with the teachings of the present invention there is provided a method of treating a disease for relieving disease associated symptoms effected by the administration a therapeutical composition including a glycosaminoglycans degrading enzyme.
- According to still another aspect of the present invention there is provided a therapeutic composition for treating a surface protected bacteria associated disease or symptoms. The comprising a glycosaminoglycans degrading enzyme and an antibiotic. Examples of antibiotics are given in the Examples section hereinunder.
- According to yet another aspect of the present invention there is provided a bactericide composition effective in eliminating a surface protected bacteria. The bactericide composition includes a glycosaminoglycans degrading enzyme and a bactericide.
- As used herein, the term “glycosaminoglycans” refers to polysaccharide-protein conjugates, such as, but not limited to, heparan sulfate, hyaluronic acid, chondroitin sulfate, keratan sulfate I, II, dermatan sulfate and heparin.
- As used herein in the specification and in the claims section below, the term “surface protected bacteria” refers to mucoid bacteria, alginate-producing bacteria and/or biofilm-producing bacteria.
- As used herein in the specification and in the claims section below, the term “anti-bacterial agent” refers to natural and man-made agents effective in killing and/or inhibiting the growth rate of bacteria. Anti-bacterial agents according to the present invention include bactericides, such as, but not limited to, biocide SDS, antibiotics and immune moieties, such as antibodies and immune cells, e.g., macrophages, T cells and the like.
- The glycosaminoglycans degrading enzyme according to the present invention can be of any type. It can be a lysosomal hydrolase or a bacterial lyase. It can be an endoglycosidase, an exoglycosidase or a sulfatase. It can, for example, be any one or combination of the following enzymes: heparanse, connective tissue activating peptide III (CTAP), hyaluronidase, glucoronidase, iduronate sulfatase, heparinase I, heparinase II heparinase III, chondroitinase ABC, chondroitinase AC, chondroitinase B and/or chondroitinase C.
- The surface-protected bacteria according to the present invention can be of any genus capable of surface protection, including, but not limited to, Pseudomonas, Azotobacter, Azomonas, Serpens, Fusobacterium, Klebsiella, Streptococcus, Staphylococcus or Treponema.Pseudomonas aeruginosa which is known to cause pulmonary infection in CF patients is of particular interest.
- Thus, the method and composition according to the present invention is effective in treating lungs of patients suffering chronic pulmonary infection, associated, for example, with cystic fibrosis, for relieving symptoms associated therewith. Treating infected lungs according to the present invention is preferably effected by an inhaler device designed to generate an aerosol of the therapeutic composition according to the present invention. Yet, the present invention is also effective in treating other organs of the body and/or other conditions, such as, but not limited to, ears, eyes, teeth, gums, wounds and bums which can be infected by surface protected bacteria.
- As used herein in the specification and in the claims section below, the term “treating” when used in conjunction with a disease refers to substantially inhibiting, slowing or reversing the progression of a disease, substantially ameliorating clinical symptoms of a disease or substantially preventing the appearance of clinical symptoms of a disease.
- For therapeutic and/or prophylactic treatment, the glycosaminoglycans degrading enzyme according to the present invention can be formulated in a composition, which may include thickeners, carriers, buffers, diluents, surface active agents, preservatives, and the like, all as well known in the art. Pharmaceutical compositions may also include one or more active ingredients such as but not limited to anti inflammatory agents, anti microbial agents, anesthetics, bactericides, antibiotics and the like in addition to the glycosaminoglycans degrading enzyme. Other enzymes, such as DNase can also be included for some applications (e.g., treatment of CF lung).
- The pharmaceutical composition can be administered in either one or more of ways depending on whether local or systemic treatment is of choice, and on the area to be treated. Administration may be done topically (including ophtalmically, vaginally, rectally, intranasally), orally, by inhalation or parenterally.
- Formulations for topical administration may include but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- Formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.
- Formulations for parenteral administration may include but are not limited to sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
- Dosing is dependent on severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with course of treatment lasting from several days to several months or until a cure is effected or a diminution of disease state is achieved. Persons ordinarily skilled in the art can easily determine optimum dosages, dosing methodologies and repetition rates.
- The method and bactericide composition according to the present invention are effective in inhibiting or killing surface protected bacteria growing on a non-living substratum, which forms, for example, a part of a medical device, such as, but not limited to, infusion device, a catheter device, a contact lens device, a dialysis device and a draining device.
- The present invention successfully addresses the shortcomings of the presently known configurations by providing new means to combat surface protected bacteria (e.g., mucoid-, alginate-, biofilm-producing bacteria), which is effected by subjecting such bacteria to GAG degrading enzyme, rendering such bacteria surface non-protected and susceptible to anti-bacterial agents and less capable of adhering to various substrata.
- Thus, according to the present invention glycosaminoglycans degrading enzymes, such as, but not limited to, heparanases, connective tissue activating peptide, heparinases, glucoronidases, heparitinases, hyaluronidases, sulfatases and chondroitinases are used, alone, in combination, or in combination with conventional substances, preferably as aerosol, for the management of diseases associated with infection by surface protected bacteria.
- The effects of glycosaminoglycans degrading enzymes on the amounts of bacterial alginate production and the associated payoffs, in addition to their effects on reducing the viscosity of sinuses and airway secretions with associated implications derived from cellular heparan sulfate degradation on curtailing the rate of infection and inflammatory responses (see U.S. patent application Ser. No. 09/046,475), will result in reduction and/or prevention of chronic infection, reduction of tissue damage, thus improving the patients quality of life and prolong life span.
- Each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the Examples section that follows.
- Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
- Bacterial strain: Clinical isolates of a mucoidPseudomonas aeruginosa strains from CF patients were kindly provided by Dr. H Berkovier from the Hadassa hospital, Ein Kerem, and Prof. E. Kerem from Shaarei Tsedek hospital, Jerusalem. Bacteria were grown on either McConkey agar plates (Hi Labs, Israel), or tryptic soy broth (TSB)+1.5% agar (Difco) or 1.5% agarose (FMC BioProducts, USA) plates, or in tryptic soy broth (Difco Laboratories, USA).
- Monosaccharide composition ofP. aeruginosa alginate: Monosaccharide composition of P. aeruginosa alginate was tested using FACE Glycosaminoglycan Identification Kit (Glyco, Inc., Novato, Calif., USA), according to manufacture's instructions.
- Reduction of alginate:
- 1. TSB+1.5% agar or 1.5% agarose plates were prepared according to manufactures instructions. Plates were covered with mucoidP. aeruginosa isolate using a cotton swab. Whatman's 25
mm 3 MM discs were then placed on the seeded bacteria. The discs were loaded with either 50 μl 0.1 μg/μl recombinant human heparanase, or 50 μl 0.1 μg/μl heat inactivated (10 min at 100° C.) recombinant human heparanase, or 50 μl heparanase buffer (10 mM buffer phosphate pH 6.8, 0.4 M NaCl, with or without 1 mM DTT), or 25 μl (3 units/μl) hyaluronidase (Sigma), or 25 μl heparinase II (0.01 unit/μl) (kindly provided by Prof. I. Vlodavsky of the Hebrew University of Jerusalem)+25 μl saline, or 25 μl (1 unit /μl) DNase (Promega)+25 μl saline, or 25 μl (0.01 u/μl) chondroitinase ABC (Sigma)+25 μl saline. The plates were incubated at 37° C. for 18 hours. The disc's surfaces were examined for the presence of mucus. Then, each disc was tapped with a bacterial needle and the bacteria were cultured 18 hours at 37° C. on TS agar plates. The phenotype of the colonies was observed and further tested for sensitivity to antibiotics. - 2. A bacterial colony was collected with a sterile tip and suspended in 500 μl saline. Fifty μl were added to a culture medium containing 50% TSB, 50% saline, 20 mM citrate-phosphate buffer pH 5.6 with either heparanase 2.5 μg/ml (50 μl), or 50 μl boiled heparanase, or 50 μl heparanase buffer. Culture was shaken 18 hours at 37° C. A sample from each tube was recultured on a TS agar plate and incubated at 37° C., 18 hours, and the cultures phenotype was recorded. 0.5 ml from each tube was sampled for viscosity testing, using microviscosometer (Haake, W. Germany).
- Resistance of mucoid vs. nonmucoid bacteria:
- Antibiotic susceptibility test discs: The enzyme-treated discs were tapped with a coffon swab that was then used to seed the “treated” bacteria onto a new TS plate. Susceptibility discs were then placed on the seeded plates and incubated for 18 hours at 37° C. The zone of inhibition of bacterial growth was measured with a ruler.
- MIC. The minimal inhibitory concentration (MIC) was determined by serial dilutions of various types of antibiotics (Enrofloxacin, sulfa/trimethoprim, gentamycin and amikacin), for variousP. aeruginosa isolates obtained.
- The effect of a combined treatment (enzyme and antibiotics) at either MIC or MIC-1, or the treatment with the enzyme followed by the antibacterial treatment at MIC, MIC-1 or MIC-2, on the number of bacteria grown was assessed by O.D. readings at 630 nm.
- In an attempt to elucidate the composition of the alginate, and find whether it has the characteristics of glycosaminoglycans making it a substrate for GAG degrading enzymes, mucoidP. aeruginosa isolate No. 1 were collected, and analyzed using the GAG identification kit. The results, which are shown in FIG. 1, indicate that the alginate has amino sugars and uronic acid and galactose, which compose the disaccharides units of the GAG.
- In order to test the possibility that GAG degrading enzymes may reduce the amount of mucoid bacteria or reduce the amount of alginate, Watmann's 3 MM disc were used following the concept of susceptibility discs. The discs were placed on a TS agar plate that was previously seeded withP. aeruginosa isolate No. 1. The results, which are shown in FIGS. 2a-e, demonstrate that discs soaked with heparanase, heparinase II and chondroitinase ABC had a dry appearance, while discs soaked with hyaluronidase, DNase, buffer, boiled heparanase and DNase were covered with mucus and had a shiny appearance. Tapping the center of each disc, and replating, revealed that the discs were contaminated by live mucoid P. aeruginosa, (not shown). After the addition of 50 μl of gentamycin at MIC-2 (3.15 μg/ml, MIC=12.5 μg/ml) to the center of each disc and incubating for 5 hours, the center of each disc was tapped with a cotton swab and the bacteria were seeded on TS plates. A variety of susceptibility discs were then placed on the seeded plates and incubated for 18 hours at 37° C. The results, which are presented in FIGS. 3a-b and Table 1 below, reveal that the bacteria that were treated by heparanase, heparinase II and chondroitinase ABC followed by gentamycin at MIC-1, were more susceptible to 5 of 7 antibiotics tested and produced less alginate, as is compared to the bacteria treated by hyaluronidase, buffer and boiled heparanase.
TABLE 1 Diameter (mm) of bacterial growth inhibition E I B Hy H-II C Amikacin 26 23 22 21 24 25 Doxylin 29 24 19 22 27 27 Ciproflox 18 15 13 12 18 17 Enroflox 21 15 13 14 18 21 Gentam 23 19 17 17 21 23 SxT ns ns ns ns ns ns Amox/Cla ns ns ns ns ns ns - In order to further establish the supposition that heparanase may induce changes in alginate producing bacterial count, changes in the total amount of alginate, and alterations in sensitivity to antibiotics,P. aeruginosa (isolate No. 40) was seeded on a TS agar plate. 3 MM discs soaked with either heparanase, boiled heparanase, heparanase-buffer, hyaluronidase or heparinase II were placed on top. After 18 hours of incubation at 37° C., the discs that were treated with heparanase, boiled heparanase, heparanase buffer and heparinase-II had a dry appearance, and the disc that was treated with hyaluronidase had a shiny appearance. This bacterial isolate produced less alginate in general and was more sensitive to antibiotics (Table 2). The disks that were soaked with either heparanase, boiled heparanase, heparinase II or hyaloronidase were then washed in 50 ml tubes containing TSB. The bacteria containing broth was further diluted and divided into 96 well plates with various antibiotics at different concentrations (MIC-1, MIC-2). The results, which are summarized in FIGS. 4a-e, show that the proliferation rate of bacteria treated previously with heparanase or heparinase II is slower compared to bacteria treated with boiled heparanase or hyaluronidase.
TABLE 2 Minimal inhibitory concentration Isolate No. Gentamycin Enrofloxacin Amikacin No. 1 12.5 6.25 25 No. 38 12.5 6.25 nd No. 39 3.12 0.78 nd No. 40 1.56 3.12 3.12 No. 41 0.78 1.56 nd - Thus, heparanase, heparinase II and chondroitinase ABC, all of which are GAG degrading enzymes, induce phenotypic changes of mucoidP. aeruginosa, exhibiting a reduced amount of alginate, slower proliferation rate and higher susceptibility to a wide range of antibiotics. The mechanism by which these enzymes induce these changes is still under investigation, yet several possible mechanisms are postulated herein in a non-limiting fashion (i) the enzymes degrade the alginate; (ii) the enzymes interfere with alginate production; (iii) the enzymes interfere with intercellular signaling for alginate production or alginate degradation by lyases; (iv) the enzymes inhibit bacterial proliferation.
- Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
Claims (41)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/140,888 US6423312B1 (en) | 1997-09-02 | 1998-08-27 | Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria |
US09/260,037 US20010006630A1 (en) | 1997-09-02 | 1999-03-02 | Introducing a biological material into a patient |
US09/978,297 US20020088019A1 (en) | 1997-09-02 | 2001-10-17 | Methods of and pharmaceutical compositions for improving implantation of embryos |
US10/163,993 US20030031660A1 (en) | 1997-09-02 | 2002-06-07 | Method of inducing bone formation |
US10/799,701 US20040175371A1 (en) | 1997-09-02 | 2004-03-15 | Introducing a biological material into a patient |
US11/154,805 US20060008892A1 (en) | 1997-09-02 | 2005-06-17 | Methods of and pharmaceutical compositions for improving implantation of embryos |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/922,170 US5968822A (en) | 1997-09-02 | 1997-09-02 | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
US09/046,475 US6153187A (en) | 1997-09-02 | 1998-03-25 | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
US09/140,888 US6423312B1 (en) | 1997-09-02 | 1998-08-27 | Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/922,170 Continuation-In-Part US5968822A (en) | 1997-09-02 | 1997-09-02 | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
US09/046,475 Continuation US6153187A (en) | 1997-09-02 | 1998-03-25 | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
US09/046,475 Continuation-In-Part US6153187A (en) | 1997-09-02 | 1998-03-25 | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/260,037 Continuation-In-Part US20010006630A1 (en) | 1997-09-02 | 1999-03-02 | Introducing a biological material into a patient |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020064858A1 true US20020064858A1 (en) | 2002-05-30 |
US6423312B1 US6423312B1 (en) | 2002-07-23 |
Family
ID=21943675
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/046,475 Expired - Fee Related US6153187A (en) | 1997-09-02 | 1998-03-25 | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
US09/140,888 Expired - Fee Related US6423312B1 (en) | 1997-09-02 | 1998-08-27 | Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/046,475 Expired - Fee Related US6153187A (en) | 1997-09-02 | 1998-03-25 | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
Country Status (3)
Country | Link |
---|---|
US (2) | US6153187A (en) |
AU (1) | AU3107799A (en) |
WO (1) | WO1999048478A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142427A1 (en) * | 1998-08-31 | 2004-07-22 | Iris Pecker | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells |
US20060263323A1 (en) * | 2003-03-24 | 2006-11-23 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
US20080085282A1 (en) * | 2006-03-31 | 2008-04-10 | Marshall University Research Corporation | Methods of detecting and controlling mucoid pseudomonas biofilm production |
US20080161763A1 (en) * | 2006-07-28 | 2008-07-03 | Becton, Dickinson And Company | Vascular access device antimicrobial materials and solutions |
US20090099341A1 (en) * | 1997-09-02 | 2009-04-16 | Insight Biopharmaceuticals Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
US20110009831A1 (en) * | 2009-07-09 | 2011-01-13 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
US20110065798A1 (en) * | 2009-09-17 | 2011-03-17 | Becton, Dickinson And Company | Anti-infective lubricant for medical devices and methods for preparing the same |
US20110184157A1 (en) * | 2008-04-29 | 2011-07-28 | Marshall University Research Corporation | Methods of Producing Bacterial Alginates |
US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010006630A1 (en) * | 1997-09-02 | 2001-07-05 | Oron Yacoby-Zeevi | Introducing a biological material into a patient |
US20040213789A1 (en) * | 1997-09-02 | 2004-10-28 | Oron Yacoby-Zeevi | Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies |
US6177545B1 (en) * | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
US20030161823A1 (en) * | 1998-08-31 | 2003-08-28 | Neta Ilan | Therapeutic and cosmetic uses of heparanases |
US20020088019A1 (en) * | 1997-09-02 | 2002-07-04 | Oron Yacoby-Zeevi | Methods of and pharmaceutical compositions for improving implantation of embryos |
US20020022005A1 (en) * | 1997-10-16 | 2002-02-21 | Budny John A. | Compositions for treating cystic fibrosis |
US20030217375A1 (en) * | 1998-08-31 | 2003-11-20 | Eyal Zcharia | Transgenic animals expressing heparanase and uses thereof |
US20040224922A1 (en) * | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
US6979563B1 (en) * | 1999-11-17 | 2005-12-27 | Biomarin Enzymes, Inc. | Attenuation of tumor growth, metastasis and angiogenesis |
EP1839671A3 (en) * | 1999-12-02 | 2007-10-31 | BioMarin Pharmaceutical Inc. | Attenuation of fibroblast proliferation |
WO2001039795A2 (en) * | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
US20040033218A1 (en) * | 2000-12-19 | 2004-02-19 | Oron Yacoby-Zeevi | Use of ecm degrading enzymes for the improvement of cell transplantation |
EP1228767A1 (en) * | 2001-01-31 | 2002-08-07 | S.A.R.M. S.r.l. | Use of beta-Glucuronidase for the treatment of immune or allergic diseases |
US6671189B2 (en) * | 2001-11-09 | 2003-12-30 | Minebea Co., Ltd. | Power converter having primary and secondary side switches |
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
ATE500842T1 (en) | 2002-05-04 | 2011-03-15 | Acorda Therapeutics Inc | COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL GROWTH |
EP1530643B1 (en) * | 2002-08-15 | 2011-05-04 | Acorda Therapeutics, Inc. | Chimeric protein |
WO2004043989A2 (en) * | 2002-11-07 | 2004-05-27 | Medarex, Inc. | Human monoclonal antibodies to heparanase |
US7959914B2 (en) * | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
JP2007532094A (en) | 2003-05-16 | 2007-11-15 | アコーダ セラピューティクス、インク. | Proteoglycan-degrading mutant for CNS treatment |
US20080025963A1 (en) * | 2003-05-16 | 2008-01-31 | Gruskin Elliott A | Compositions and methods for the treatment of CNS injuries |
WO2004108065A2 (en) * | 2003-06-09 | 2004-12-16 | Insight Biopharmaceuticals Ltd. | Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies |
DK1658063T3 (en) | 2003-08-06 | 2014-05-12 | Galephar M F | BENEFICIAL COMBINATIONS FOR INHALATION OF NACYSTLINE AND SOURCE CODILATORS |
US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
US20130211320A1 (en) * | 2003-10-07 | 2013-08-15 | Nawar Alkhamesi | System and method for delivering an anti-adhesive substance to a body cavity |
ES2411504T3 (en) * | 2004-05-18 | 2013-07-05 | Acorda Therapeutics, Inc. | Chondroitinase purification methods and stable formulations thereof |
JP5189985B2 (en) | 2005-09-26 | 2013-04-24 | アコーダ セラピューティクス、インク. | Composition using chondroitinase ABCI mutant and method of using the same |
WO2008008494A2 (en) * | 2006-07-13 | 2008-01-17 | Accentia Biopharmaceuticals, Inc. | Methods and compositions for treating mucosal inflammation |
US20090202514A1 (en) * | 2006-08-25 | 2009-08-13 | Hiroyuki Yoneyama | Agents for improving chronic obstructive pulmonary diseases |
JP5391069B2 (en) | 2006-10-10 | 2014-01-15 | アコーダ セラピューティクス、インク. | Compositions and methods using chondroitinase ABCI variants |
US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
AR086745A1 (en) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE |
BR112015014178A2 (en) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | 3,5-diamino-6-chloro-n- (n- (4-phenylbutyl) carbamimidoyl) pyrazine-2-carboxamide compounds |
BR112015014349A2 (en) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favored by insufficient mucosal hydration |
US20160120898A1 (en) | 2013-05-23 | 2016-05-05 | Breathe Easy Limited | Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
WO2019051297A1 (en) * | 2017-09-08 | 2019-03-14 | The Nemours Foundation | An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2065744A1 (en) * | 1989-08-23 | 1991-02-24 | Zvi Fuks | Wound healing preparations containing heparanase |
AU4859793A (en) * | 1992-09-11 | 1994-04-12 | Regents Of The University Of California, The | Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation |
JP3309188B2 (en) | 1992-12-28 | 2002-07-29 | 大塚化学株式会社 | Alginate lyase |
US5474983A (en) * | 1993-03-15 | 1995-12-12 | The Research Foundation Of State University Of New York | Method of inhibiting pro-inflammatory mediator release from basophils and mast cells |
JPH099962A (en) | 1995-06-23 | 1997-01-14 | Akira Nakagawa | Alginic acid hydrolyzing enzyme and hydrolysis of alginic acid |
CA2233343A1 (en) * | 1995-09-29 | 1997-04-03 | Ibex Technologies Inc. | Use of heparinases to decrease inflammatory responses |
CA2285940A1 (en) * | 1997-04-11 | 1998-10-22 | K. Ramakrishnan Bhaskar | Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions |
-
1998
- 1998-03-25 US US09/046,475 patent/US6153187A/en not_active Expired - Fee Related
- 1998-08-27 US US09/140,888 patent/US6423312B1/en not_active Expired - Fee Related
-
1999
- 1999-03-22 AU AU31077/99A patent/AU3107799A/en not_active Abandoned
- 1999-03-22 WO PCT/US1999/006189 patent/WO1999048478A1/en active Application Filing
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048993B2 (en) | 1997-09-02 | 2011-11-01 | Insight Biopharmaceuticals Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
US20090099341A1 (en) * | 1997-09-02 | 2009-04-16 | Insight Biopharmaceuticals Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
US20040142427A1 (en) * | 1998-08-31 | 2004-07-22 | Iris Pecker | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells |
US20060263323A1 (en) * | 2003-03-24 | 2006-11-23 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
US20080085282A1 (en) * | 2006-03-31 | 2008-04-10 | Marshall University Research Corporation | Methods of detecting and controlling mucoid pseudomonas biofilm production |
US7781166B2 (en) | 2006-03-31 | 2010-08-24 | Marshall University Research Corporation | Methods of detecting and controlling mucoid pseudomonas biofilm production |
US20110008786A1 (en) * | 2006-03-31 | 2011-01-13 | Marshall University Research Corporation | Methods of detecting and controlling mucoid pseudomonas biofilm production |
US8399649B2 (en) | 2006-03-31 | 2013-03-19 | Marshall University Research Corporation | Methods of detecting and controlling mucoid Pseudomonas biofilm production |
US20080161763A1 (en) * | 2006-07-28 | 2008-07-03 | Becton, Dickinson And Company | Vascular access device antimicrobial materials and solutions |
US8512294B2 (en) | 2006-07-28 | 2013-08-20 | Becton, Dickinson And Company | Vascular access device antimicrobial materials and solutions |
US9175322B2 (en) | 2008-04-29 | 2015-11-03 | Marshall University Research Corporation | Stable bacterial cultures for producing alginates |
US20110184157A1 (en) * | 2008-04-29 | 2011-07-28 | Marshall University Research Corporation | Methods of Producing Bacterial Alginates |
US8821455B2 (en) | 2009-07-09 | 2014-09-02 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
US20110009831A1 (en) * | 2009-07-09 | 2011-01-13 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
US20110065798A1 (en) * | 2009-09-17 | 2011-03-17 | Becton, Dickinson And Company | Anti-infective lubricant for medical devices and methods for preparing the same |
US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
US11357962B2 (en) | 2013-02-13 | 2022-06-14 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
US9789280B2 (en) | 2013-03-11 | 2017-10-17 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US9956379B2 (en) | 2014-04-23 | 2018-05-01 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
US10589063B2 (en) | 2014-04-23 | 2020-03-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US11357965B2 (en) | 2014-04-23 | 2022-06-14 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
US11219705B2 (en) | 2014-07-08 | 2022-01-11 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
US11904114B2 (en) | 2015-10-28 | 2024-02-20 | Becton, Dickinson And Company | Extension tubing strain relief |
Also Published As
Publication number | Publication date |
---|---|
WO1999048478A1 (en) | 1999-09-30 |
AU3107799A (en) | 1999-10-18 |
US6423312B1 (en) | 2002-07-23 |
US6153187A (en) | 2000-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6423312B1 (en) | Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria | |
Tolker‐Nielsen | Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities | |
US8580551B2 (en) | Dispersin B polypeptides and uses thereof | |
Kaplan et al. | Enzymatic detachment of Staphylococcus epidermidis biofilms | |
Nyč et al. | Stenotrophomonas maltophilia: significant contemporary hospital pathogen | |
Starkey et al. | A sticky business: the extracellular polymeric substance matrix of bacterial biofilms | |
Palmer | Bacterial biofilms in chronic rhinosinusitis | |
Young et al. | Streptococcus pyogenes biofilm | |
SG191146A1 (en) | A composition comprising an antibiotic and a dispersant or an anti -adhesive agent | |
JP2011505340A (en) | Use of alginate oligomers in combating biofilms | |
CA2800514C (en) | Use of streptococcus salivarius in the treatment of chronic infections of the respiratory tract | |
Kenna et al. | Microbiology of chronic suppurative otitis media in children | |
Schurek et al. | Pseudomonas aeruginosa: a persistent pathogen in cystic fibrosis and hospital-associated infections | |
Wu et al. | Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa | |
US8906393B2 (en) | Biofilm inhibiting composition | |
Ali et al. | Molecular study of some virulence genes of Pseudomonas aeruginosa isolated from different infections in hospitals of Baghdad | |
Yang et al. | Biofilm tolerance, resistance and infections increasing threat of public health | |
Carreer et al. | Oxidant-scavenging activities of beta-lactam agents | |
EP1545490A1 (en) | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract | |
Kalfa et al. | Anionic antimicrobial peptide-lysozyme interactions in innate pulmonary immunity | |
Rikalovic et al. | Structure-Function relationships of rhamnolipid and exopolysacharide biosurfactants of Pseudomonas aeruginosa as therapeutic targets in cystic fibrosis lung infections | |
Kutsuno et al. | Non-deacetylated poly-N-acetylglucosamine-hyperproducing Staphylococcus aureus undergoes immediate autoaggregation upon vortexing | |
Peterson | Investigations of Substrate Recognition of the Biofilm Glycosidase Enzyme Dispersin B | |
McCubbin et al. | Pathogenesis of Pseudomonas lung disease in cystic fibrosis | |
Milligan | Hyaluronic acid production in Streptococcus equi species |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INSIGHT STRATEGY & MARKETING LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YACOBY-ZEEVI, ORON;REEL/FRAME:009434/0980 Effective date: 19980822 |
|
AS | Assignment |
Owner name: INSIGHT BIOPHARMACEUTICALS LTD., ISRAEL Free format text: CHANGE OF NAME;ASSIGNOR:INSIGHT STRATEGY & MARKETING LTD.;REEL/FRAME:015438/0847 Effective date: 20030819 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100723 |